PLYX:NASDAQ, Polaryx Therapeutics Inc.

Why PLYX stock fell on November 20

Polaryx Therapeutics Inc. fell 11.9% on Friday, November 20, 2026, on 49,399 shares. The headline around the move:

PLYX stock overview

Polaryx Therapeutics Inc. (PLYX:NASDAQ) closed at $1.33 on November 20, 2026, down 11.92% on the day. The stock trades 97.3% below its 52-week high of $48.91 and 2.3% above its 52-week low of $1.30. Over the past year, it lost 96.2%. Polaryx Therapeutics Inc. is part of the Health Care sector.

Key figures

Price
$1.33
Day change
-11.92%
Volume
49,399
Average volume
37,345
Market cap
66M+
52-week range
$1.30 – $48.91
50-day average
$1.93
200-day average
$3.18

Price action over the past year

In 203 trading sessions since February 3, 2026, PLYX closed higher on 84 days (41%). Its best day was March 10, 2026 (+69.60%) and its worst was February 6, 2026 (-44.31%). The stock moved 10% or more in a single session 36 times. It opened at least 5% above the previous day's high 2 times.

Recent signals

PLYX news

About Polaryx Therapeutics Inc.

Polaryx Therapeutics is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders ("LSDs"). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs. Our most advanced product candidate, PLX-200, targets several LSDs and we intend to launch a Phase 2 proof-of-concept basket trial which may enhance PLX-200's potential to become the standard of care across multiple LSDs.

Similar stocks

Find more stocks like PLYX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.